Literature DB >> 4825224

Effects of dobutamine on left ventricular performance, coronary dynamics, and distribution of cardiac output in conscious dogs.

S F Vatner, R J McRitchie, E Braunwald.   

Abstract

The effects of dobutamine ([+/-]-4-[2-[[3-(p-hydroxyphenyl)-1-methyl propyl] amino] ethyl] pyrocatechol hydrochloride), a new synthetic cardioactive sympathomimetic amine, were examined on direct and continuous measurements of left ventricular (LV) diameter (D), pressures (P), velocity of shortening (V), dP/dt, dP/dt/P, arterial pressure, cardiac output, and regional blood flows in the left circumflex coronary, mesenteric, renal, and iliac beds in healthy, conscious dogs. At the highest dose of dobutamine examined, 40 mug/kg/min, the drug increased dP/dt/P from 65+/-3 to 128+/-4 s(-1) and isolength velocity from 72+/-4 to 120+/-7 mm/s without affecting LV end diastolic D significantly. Mean arterial P rose from 92+/-2 to 104+/-3 mm Hg and heart rate from 78+/-3 to 111+/-7 beats/min, while LV end systolic D fell from 24.1+/-1.4 to 19.9+/-1.8 mm, reflecting a rise in stroke volume from 30+/-4 to 42+/-3 ml. Cardiac output rose from 2.41+/-0.23 to 4.35+/-0.28 liter/min, while calculated total peripheral resistance declined from 0.042+/-0.005 to 0.028+/-0.003 mm Hg/ml/min. The greatest increases in flow and decreases in calculated resistance occurred in the iliac and coronary beds, and the least occurred in the renal bed. Propranolol blocked the inotropic and beta(2) dilator responses while vasoconstricting effects mediated by alpha adrenergic stimulation remained in each of the beds studied. When dobutamine was infused after a combination of practolol and phentolamine, dilatation occurred in each of the beds studied. These observations indicate that dobutamine is a potent positive inotropic agent with relatively slight effects on preload, afterload, or heart rate, and thus may be a potentially useful clinical agent. The one property of this drug which is not ideal is its tendency to cause a redistribution of cardiac output favoring the muscular beds at the expense of the kidney and visceral beds.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4825224      PMCID: PMC302613          DOI: 10.1172/JCI107673

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  20 in total

1.  Technique for radio telemetry of blood-flow velocity from unrestrained animals.

Authors:  D E Franklin; N W Watson; K E Pierson; R L Van Citters
Journal:  Am J Med Electron       Date:  1966

2.  The treatment of cardiogenic shock. VI. The search for an ideal drug.

Authors:  L I Goldberg
Journal:  Am Heart J       Date:  1968-03       Impact factor: 4.749

3.  Simultaneous comparison and calibration of the Doppler and electromagnetic flowmeters.

Authors:  S F Vatner; D Franklin; R L VanCitters
Journal:  J Appl Physiol       Date:  1970-12       Impact factor: 3.531

4.  Factors influencing infarct size following experimental coronary artery occlusions.

Authors:  P R Maroko; J K Kjekshus; B E Sobel; T Watanabe; J W Covell; J Ross; E Braunwald
Journal:  Circulation       Date:  1971-01       Impact factor: 29.690

5.  Effects of isoproterenol on hemodynamic alterations, myocardial metabolism, and coronary flow in experimental acute myocardial infarction with shock.

Authors:  L A Kuhn; H J Kline; P Goodman; C D Johnson; A J Marano
Journal:  Am Heart J       Date:  1969-06       Impact factor: 4.749

6.  A hemodynamic comparison of dopamine and isoproterenol in patients in shock.

Authors:  R C Talley; L I Goldberg; C E Johnson; J L McNay
Journal:  Circulation       Date:  1969-03       Impact factor: 29.690

7.  Assessment of cardiac contractility. The relation between the rate of pressure rise and ventricular pressure during isovolumic systole.

Authors:  D T Mason; E Braunwald; J W Covell; E H Sonnenblick; J Ross
Journal:  Circulation       Date:  1971-07       Impact factor: 29.690

8.  Hemodynamic studies in cardiogenic shock. Treatment with isoproterenol and metaraminol.

Authors:  H J Smith; A Oriol; J Morch; M McGregor
Journal:  Circulation       Date:  1967-06       Impact factor: 29.690

9.  Ineffectiveness of isoproterenol in shock due to acute myocardial infarction.

Authors:  R M Gunnar; H S Loeb; R J Pietras; J R Tobin
Journal:  JAMA       Date:  1967-12-25       Impact factor: 56.272

10.  Hemodynamics, coronary blood flow, and myocardial metabolism in coronary shock; response of 1-norepinephrine and isoproterenol.

Authors:  H Mueller; S M Ayres; J J Gregory; S Giannelli; W J Grace
Journal:  J Clin Invest       Date:  1970-10       Impact factor: 14.808

View more
  34 in total

1.  Use of ivabradine in catecholamine-induced tachycardia after high-risk cardiac surgery.

Authors:  Domenico Vitale; Vincenzo De Santis; Fabio Guarracino; Andrea Fontana; Fabio Pellegrini; Luigi Tritapepe
Journal:  Clin Res Cardiol       Date:  2010-09-07       Impact factor: 5.460

2.  Haemodynamic profile of an inhibitor of phosphodiesterase III, adibendan (BM 14.478): comparison with nitroprusside and dobutamine in conscious dogs.

Authors:  A Dorszewski; B Müller-Beckmann; L Kling; G Sponer
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

3.  Comparative haemodynamic effects of dobutamine and isoproterenol in man.

Authors:  M Rigaud; J Boschat; P Rocha; A Ferreira; J Bardet; J P Bourdarias
Journal:  Intensive Care Med       Date:  1977-08       Impact factor: 17.440

4.  Cardiovascular effects of a new inotropic agent, U. K. 14275, in patients with coronary heart disease.

Authors:  I Hutton; W S Hillis; C E Langhan; J M Conely; T D Lawrie
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

5.  A novel catecholamine, arbutamine, for a pharmacological cardiac stress agent.

Authors:  R Nagarajan; G Abou-Mohamed; T Myers; R W Caldwell
Journal:  Cardiovasc Drugs Ther       Date:  1996-03       Impact factor: 3.727

6.  Characterization of the adrenergic activity of arbutamine, a novel agent for pharmacological stress testing.

Authors:  G Abou-Mohamed; R Nagarajan; T M Ibrahim; R W Caldwell
Journal:  Cardiovasc Drugs Ther       Date:  1996-03       Impact factor: 3.727

7.  Comparison of dobutamine and dopamine in treatment of severe heart failure.

Authors:  J D Stoner; J L Bolen; D C Harrison
Journal:  Br Heart J       Date:  1977-05

8.  Cardiogenic shock. Current concepts in management.

Authors:  K Balakumaran; P G Hugenholtz
Journal:  Drugs       Date:  1986-10       Impact factor: 9.546

9.  The cardiovascular pharmacology of 7-propyl-theo-phylline-dopamine (D4975); comparison with dopamine and dobutamine.

Authors:  D McCaig; J R Parratt
Journal:  Br J Pharmacol       Date:  1979-10       Impact factor: 8.739

10.  The use of dobutamine in myocardial infarction for reversal of the cardiodepressive effect of metoprolol.

Authors:  F Waagstein; I Malek; A C Hjalmarson
Journal:  Br J Clin Pharmacol       Date:  1978-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.